肝炎E:一个正在等待的病毒.

Same author

Urinary phenylacetylglutamine (U-PAGN) concentration as biomarker for adherence in patients with urea cycle disorders (UCD) treated with glycerol phenylbutyrate.

Molecular genetics and metabolism reports·2017

Same author

Overt hepatic encephalopathy: development of a novel clinician reported outcome tool and electronic caregiver diary.

Metabolic brain disease·2016

Same author

Refeeding syndrome in a young woman with argininosuccinate lyase deficiency.

Molecular genetics and metabolism reports·2016

Same author

Prospective Multicenter Observational Study of Overt Hepatic Encephalopathy.

Digestive diseases and sciences·2016

Same author

Glutamine and hyperammonemic crises in patients with urea cycle disorders.

Molecular genetics and metabolism·2015

Same author

Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.

Molecular genetics and metabolism·2013

Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026

Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026

Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026

Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026

Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026

Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026

相关实验视频

肝炎E:一个正在等待的病毒.

相关概念视频

Urinary phenylacetylglutamine (U-PAGN) concentration as biomarker for adherence in patients with urea cycle disorders (UCD) treated with glycerol phenylbutyrate.

Overt hepatic encephalopathy: development of a novel clinician reported outcome tool and electronic caregiver diary.

Refeeding syndrome in a young woman with argininosuccinate lyase deficiency.

Prospective Multicenter Observational Study of Overt Hepatic Encephalopathy.

Glutamine and hyperammonemic crises in patients with urea cycle disorders.

Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

相关实验视频

肝炎E:一个正在等待的病毒.

相关概念视频

相关文章

Urinary phenylacetylglutamine (U-PAGN) concentration as biomarker for adherence in patients with urea cycle disorders (UCD) treated with glycerol phenylbutyrate.

Overt hepatic encephalopathy: development of a novel clinician reported outcome tool and electronic caregiver diary.

Refeeding syndrome in a young woman with argininosuccinate lyase deficiency.

Prospective Multicenter Observational Study of Overt Hepatic Encephalopathy.

Glutamine and hyperammonemic crises in patients with urea cycle disorders.

Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.